

For more information about the HER2-RADiCAL study, please speak to a member of your hospital breast team or oncology team.

Contact details for the team responsible for HER2-RADiCAL at this site:

.....
.....

The HER2-RADiCAL study is sponsored and co-ordinated by The Institute of Cancer Research. It has been approved by the National Institute for Health Research—Health Technology Assessment (HTA) Programme, Health Research Authority (HRA), the London - South East Research Ethics Committee, the UK regulatory Agency (MHRA) and the study Sponsor's Committee for Clinical Research.

Resources

You can learn more about clinical trials on the Cancer Research UK's patient website (www.cancerhelp.org.uk).

Macmillan Cancer Support is a registered charity providing information, emotional support and publications about all aspects of cancer for cancer patients and their families. You can contact one of their Cancer Information nurse specialists on the Macmillan Support Line: Freephone 0808 808 00 00 Monday to Friday, 9.00am to 8.00pm. In addition to their nurses, the Macmillan Support Line also has other specialist teams that can provide advice and information relating to welfare benefits, financial issues and everyday practical concerns.

You can also learn more about clinical trials on the Cancer Research UK's patient website <http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial>.

Thank you for taking the time to read this leaflet.



Tailoring treatment for HER2-positive early breast cancer

Are you receiving
treatment before your
surgery for HER2-positive
breast cancer?

The HER2-RADiCAL study may
be a suitable option for you in
the future.

ICR The Institute of
Cancer Research

NIHR | National Institute
for Health Research

What does “tailoring treatment for HER2-positive early breast cancer” mean?

In recent years it has become standard practice for patients with HER2-positive early breast cancer to start treatment *before* surgery. This gives doctors the opportunity to measure how this treatment given before surgery has worked for each patient.

Doctors can then use this information to tailor the patient’s remaining treatment plan according to how they have responded to this treatment given before surgery. A more personalised treatment plan can then be developed for each patient’s treatment following surgery.

The aim of a personalised treatment plan is to improve the chance of a patient doing well, while minimising the likelihood of the patient developing side effects from the treatment.

What does this mean for me?

You have HER2-positive breast cancer and are currently receiving treatment before surgery

You will have your surgery and tests will be conducted on the tissue samples removed to see how your cancer has responded to treatment

Doctors will examine the tissue removed during surgery under a microscope. If there are no living cancer cells left, this is called a “pathological complete response” (“pCR”).

If the tests show that you have had a pCR, a research study called HER2-RADiCAL may be a suitable option for you.

Participation in HER2-RADiCAL is entirely voluntary. If you choose not to participate this will not affect the standard of care you receive.

If the tests show that you have not had a pCR, there are other treatment options available that are tailored to your type of cancer.

Your doctor will discuss your options with you.

What is HER2-RADiCAL?

HER2-RADiCAL is a research study that will investigate whether patients who have had this “pCR” response to treatment before surgery can safely receive less drug treatment after surgery, without increasing the risk of their cancer returning. We think that this will spare some patients the side effects and disadvantages of a longer course of treatment.

What happens now?

You do not need to do anything at the moment. You will continue your current treatment and have your surgery as planned.

If your doctor confirms that HER2-RADiCAL is a suitable option, you will be able to consider participating in this study. You will be given another patient information sheet which will provide more detail on what the study involves, including the risks and benefits.

If HER2-RADiCAL is not a suitable option for you, your doctor will discuss treatment options and whether there are other suitable research studies for you.